Global Bladder Cancer Therapeutics Market – Industry Trends and Forecast to 2030

Global Bladder Cancer Therapeutics Market, By Type (Transitional Cell Bladder Cancer, Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Others), End-Users (Hospitals, Specialty Clinics, Others), Treatment (Surgery, Chemotherapy, Immunotherapy Radiation Therapy, Others), Major Tests (Cytoscopy, Biopsy, Urinalysis, Urine Cytology and Bladder Ultrasound) Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.

Bladder Cancer Therapeutics Market Analysis and Size

According to GLOBOCAN 2020's updated data predictions, 573,278 people will be diagnosed with bladder cancer globally in 2020, making it the world's tenth most common cancer. Men will be diagnosed with bladder cancer in 440,864 new cases worldwide, accounting for 4.4 percent of all new cases, according to the new data. Bladder cancer is the sixth most common type of cancer in men worldwide. Global healthcare spending has increased at an alarming rate in recent years. As a result, new medical technology, therapies, and medicines for bladder cancer disorders are now available, significantly contributing to the overall increase in healthcare expenditures. High drug prices, drug patent expiration, and the expense of healthcare can all be attributed to the two-thirds increase in healthcare spending.

Data Bridge Market Research analyses that the bladder cancer therapeutics market, which was USD 266.10 million in 2022, is expected to reach USD 409.93 million by 2030, at a CAGR of 5.55% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Bladder Cancer Therapeutics Market Scope and Segmentation  

Market Definition

Bladder cancer is defined as the uncontrolled growth of abnormal cells in the urinary bladder and typically affects older adults. The spread of cancerous cells into the bladder's muscular wall is dangerous to one's health, so early detection is essential. The most common treatments for bladder cancer are surgery, biological therapy, and chemotherapy, and the main cause of cancer occurrences can be tobacco use and exposure to certain toxic chemicals and gases. Bladder cancer is the fourth most common type of cancer in men, but it is less common in women.

Global Bladder Cancer Therapeutics Market Dynamics

Drivers

• Rise in Immunotherapy

The appeal of immunotherapy is growing rapidly, due to the limitations of conventional therapies. It is estimated that nearly USD 50 billion spent on cancer treatments annually benefits no patients. Immunotherapy has emerged as a promising therapy for the treatment of bladder cancer. As a result, immunotherapy for bladder cancer is becoming increasingly popular.

• Development of new cancer-targeting drugs

With a better understanding of tumour immunology, scientists can now develop new cancer-targeting drugs. The PD-L1 inhibitors TECENTRIQ and OPDIVO were recently approved by the US FDA for the treatment of urothelial carcinoma. Cystoscopy, one of the most effective procedures for diagnosing bladder cancer, involves the use of a long thin tube called a cystoscope. This allows the urologist to extract a small piece of the abnormal tissue for examination by pathologists. With the development of effective diagnostic tools such as the flexible cystoscope, urologists will prefer cystoscopy because it can be performed easily in the outpatient setting. One of the major trends that will gain traction in the bladder is the development of effective diagnostic tools. These are the certain factors which help the market to grow.

Opportunities

• Introduction of novel drugs

The antibody-drug conjugates (ADCs) enfortumab vedotin (EV) and sacituzumab govitecan (SG) have demonstrated the ability to provide objective response rates (ORRs) of 44% and 31% in patients with bladder tumour cells that express Nectin-4 and Trop-2, respectively. As a result, the FDA approved EV for the treatment of patients with advanced or metastatic bladder cancer who have previously received ICI and platinum-containing chemotherapy.

Restraints/Challenges

• High cost

The high costs of bladder cancer therapies and asymptomatic nature of the disease may restrain the market growth.

This bladder cancer therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bladder cancer therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent developments

• On January 7, 2020, Pfizer and Merck KGaA jointly announced that the PD-L1 inhibitor Bavencio had been approved by the US FDA. They also stated that this evaluates positive data from a phase III study's interim analysis and will soon show better results in patients with advanced/metastatic urothelial cancer, a type of bladder cancer.

Global Bladder Cancer Therapeutics Market Scope

The bladder cancer therapeutics market is segmented on the basis of type, treatment, major tests, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Transitional Cell Bladder Cancer
• Superficial Bladder Cancer
• Invasive Bladder Cancer
• Squamous Cell Bladder Cancer
• Others

 End-Users

• Hospitals
• Specialty Clinics
• Others

Treatment

• Surgery
• Transurethral bladder tumor resection (TURBT)
• Cystectomy
• Urinary Diversion
• Chemotherapy
• Intravesical (local) Chemotherapy
• Systemic (whole body) Chemotherapy
• Immunotherapy Radiation Therapy
• Intravesical TherapyInterferon Therapy

 Major Tests

• Cytoscopy
• Biopsy
• Urinalysis
• Urine Cytology
• Bladder Ultrasound

 Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Bladder Cancer Therapeutics Market Regional Analysis/Insights

The bladder cancer therapeutics market is analyzed and market size insights and trends are provided by type, treatment, major tests, end-users and distribution channel as referenced above.

The countries covered in the bladder cancer therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the bladder cancer therapeutics market due to the presence of key manufacturers of the product is high and increasing research and development activities, healthcare expenditure contributes raising the significant growth of the market.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to improved new research and developments on bladder cancer therapeutics market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The bladder cancer therapeutics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for bladder cancer therapeutics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the bladder cancer therapeutics market. The data is available for historic period 2011-2021.

Competitive Landscape and Bladder Cancer Therapeutics Market Share Analysis

The bladder cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bladder cancer therapeutics market.

Some of the major players operating in the bladder cancer therapeutics market are:

• AstraZeneca (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Lilly (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Sanofi (France)
• Endo Pharmaceuticals Inc. (Ireland)
• Johnson & Johnson Services, Inc. (U.S.)
• Celgene Corporation (U.S.)

Research Methodology: Global Bladder Cancer Therapeutics Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.